UNI-EN 5:Current report 5 on exceeding 5% in the capital of Hydroizomat AD 13012012
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| | UNI - EN REPORT No | 5 | / | 2012 | | ||||||
| Date of issue: | 2012-01-13 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Current report 5 on exceeding 5% in the capital of Hydroizomat AD 13012012 | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| ACQUISITION OF OWN SHARES Current report No. 5/2012 Dated 13 January 2012 The Board of Directors of SOPHARMA AD (the “Company") hereby informs that on January 06 2012 the Company bought 11 150 shares from the capital of the company Hydroizomat AD. With this deal Sopharma AD has increased its holdings in the capital of the above-mentioned company over 5%. Sopharma AD now holds 65 222 shares or 5.02% of the capital of Hydroizomat AD. The total capital of the company is 1 299 122 shares. The transaction was conducted on the unofficial market of the Bulgarian Stock Exchange – Sofia AD Segment B. This transaction was not carried out with the purpose of gaining control. Sopharma AD is not a member of the management board of Hydroizomat AD. Legal grounds: Art. 145 of the Act on Public Offering of Securities, Bulgaria. Signatures of individuals authorized to represent the Company Ognian Donev | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Current report 5 on exceeding 5% in the capital of Hydroizomat AD 13012012.doc Current report 5 on exceeding 5% in the capital of Hydroizomat AD 13012012.doc | Current report 5 on exceeding 5% in the capital of Hydroizomat AD 13012012 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2012-01-13 | Ognian Donev | Executive Direcotr | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to None PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
